Medicare Program; Application by the Utilization Review Accreditation Commission (URAC) for Continued CMS Approval of Its Home Infusion Therapy (HIT) Accreditation Program, 77321-77323 [2023-24850]
Download as PDF
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 216 / Thursday, November 9, 2023 / Notices
appropriate component office of the
Commission.
The FMC will implement a new web
portal, the FMC Assistance Center,
available through the agency’s website
to collect this information from the
public. The collected information will
be internally routed to the appropriate
component office for response. As this
collection includes inquiries related to
dispute resolution services, it also
encompasses Forms FMC–32 (Dispute
Resolution Service Request—Cruise)
and FMC–33 (Dispute Resolution
Service Request—Cargo). Forms FMC–
32 and FMC 33 have been modified in
the Affirmation section to remove a
statement directing the public to a link
on the agency web page and to add a
statement that the matter will be closed
if false statements and documents are
provided. These forms and the
Assistance Center screen mock-ups are
included in this docket. The burden
associated with these forms is included
in this collection.
Current Actions: The information
being submitted contains a new data
collection.
Type of Review: New information
collection.
Needs and Uses: The Commission
will use the FMC Assistance Center
(web portal) to receive requests from the
public and ensure prompt response to
the shipping public.
Frequency: This information will be
collected when members of the public
choose to submit it.
Type of Respondents: Individuals and
establishments who wish to ask
questions, express concerns, or submit
complaints to the Federal Maritime
Commission.
Number of Annual Respondents: The
Commission estimates an annual
respondent universe of 5,000. The
Commission further estimates 300 of
these responses will require attaching
an FMC form related to dispute
resolution services (FMC–32 or FMC–
33).
Estimated Time per Response: The
time per response is estimated at 6
minutes per response for submissions
that do not involve attaching forms and
20 minutes for responses requiring
attaching forms.
Total Annual Burden: Burden is
calculated as 4,700 × 6 minutes = 470
hours per portal submission that does
not also include a form and 300 × 20
minutes = 100 hours for a submission
that also includes either FMC–32 or
VerDate Sep<11>2014
18:22 Nov 08, 2023
Jkt 262001
FMC–33. Total burden equals 570
hours.
Carl Savoy,
Federal Register Alternate Liaison Officer.
[FR Doc. 2023–24785 Filed 11–8–23; 8:45 am]
BILLING CODE 6730–02–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS 3452–PN]
Medicare Program; Application by the
Utilization Review Accreditation
Commission (URAC) for Continued
CMS Approval of Its Home Infusion
Therapy (HIT) Accreditation Program
Centers for Medicare &
Medicaid Services (CMS), Health and
Human Services (HHS).
ACTION: Notice with request for
comment.
AGENCY:
This notice acknowledges the
receipt of an application from the
Utilization Review Accreditation
Commission (URAC) for continued
approval by the Centers for Medicare &
Medicaid Services (CMS) of URAC’s
national accrediting organization
program for suppliers providing home
infusion therapy (HIT) services and that
wish to participate in the Medicare or
Medicaid programs. The statute requires
that within 60 days of receipt of an
organization’s complete application,
CMS will publish a notice that identifies
the national accrediting body making
the request, describes the nature of the
request, and provides at least a 30-day
public comment period.
DATES: To be assured consideration,
comments must be received at one of
the addresses provided below, by
December 11, 2023.
ADDRESSES: In commenting, refer to file
code CMS–3452–PN.
Comments, including mass comment
submissions, must be submitted in one
of the following three ways (please
choose only one of the ways listed):
1. Electronically. You may submit
electronic comments on this regulation
to https://www.regulations.gov. Follow
the ‘‘Submit a comment’’ instructions.
2. By regular mail. You may mail
written comments to the following
address ONLY: Centers for Medicare &
Medicaid Services, Department of
Health and Human Services, Attention:
CMS–3452–PN, P.O. Box 8016,
Baltimore, MD 21244–8010.
SUMMARY:
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
77321
Please allow sufficient time for mailed
comments to be received before the
close of the comment period.
3. By express or overnight mail. You
may send written comments to the
following address ONLY: Centers for
Medicare & Medicaid Services,
Department of Health and Human
Services, Attention: CMS–3452–PN,
Mail Stop C4–26–05, 7500 Security
Boulevard, Baltimore, MD 21244–1850.
For information on viewing public
comments, see the beginning of the
SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT:
Shannon Freeland, (410) 786–4348.
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All
comments received before the close of
the comment period are available for
viewing by the public, including any
personally identifiable or confidential
business information that is included in
a comment. We post all comments
received before the close of the
comment period on the following
website as soon as possible after they
have been received: https://
www.regulations.gov. Follow the search
instructions on that website to view
public comments. We will not post on
Regulations.gov public comments that
make threats to individuals or
institutions or suggest that the
individual will take actions to harm the
individual. We continue to encourage
individuals not to submit duplicative
comments. We will post acceptable
comments from multiple unique
commenters even if the content is
identical or nearly identical to other
comments.
I. Background
Home infusion therapy (HIT) is a
treatment option for Medicare
beneficiaries with a wide range of acute
and chronic conditions. Section 5012 of
the 21st Century Cures Act (Pub. L. 114–
255, enacted December 13, 2016) added
section 1861(iii) to the Social Security
Act (the Act), establishing a new
Medicare benefit for HIT services.
Section 1861(iii)(1) of the Act defines
‘‘home infusion therapy’’ as professional
services, including nursing services;
training and education not otherwise
covered under the Durable Medical
Equipment (DME) benefit; remote
monitoring; and other monitoring
services. HIT must be furnished by a
qualified HIT supplier and furnished in
the individual’s home. The individual
must:
• Be under the care of an applicable
provider (that is, physician, nurse
practitioner, or physician assistant); and
• Have a plan of care established and
periodically reviewed by a physician in
E:\FR\FM\09NON1.SGM
09NON1
77322
Federal Register / Vol. 88, No. 216 / Thursday, November 9, 2023 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
coordination with the furnishing of
home infusion drugs under Part B, that
prescribes the type, amount, and
duration of infusion therapy services
that are to be furnished.
Section 1861(iii)(3)(D)(i)(III) of the Act
requires that a qualified HIT supplier be
accredited by an accrediting
organization (AO) designated by the
Secretary in accordance with section
1834(u)(5) of the Act. Section
1834(u)(5)(A) of the Act identifies
factors for designating AOs and in
reviewing and modifying the list of
designated AOs. These statutory factors
are as follows:
• The ability of the organization to
conduct timely reviews of accreditation
applications.
• The ability of the organization to
take into account the capacities of
suppliers located in a rural area (as
defined in section 1886(d)(2)(D) of the
Act).
• Whether the organization has
established reasonable fees to be
charged to suppliers applying for
accreditation.
• Such other factors as the Secretary
determines appropriate.
Section 1834(u)(5)(B) of the Act
requires the Secretary to designate AOs
to accredit HIT suppliers furnishing HIT
not later than January 1, 2021. Section
1861(iii)(3)(D)(i)(III) of the Act requires
a ‘‘qualified home infusion therapy
supplier’’ to be accredited by a CMSapproved AO, pursuant to section
1834(u)(5) of the Act.
On March 1, 2019, we published a
solicitation notice entitled, ‘‘Medicare
Program; Solicitation of Independent
Accrediting Organizations to Participate
in the Home Infusion Therapy Supplier
Accreditation Program’’ (84 FR 7057).
This notice informed national AOs that
accredit HIT suppliers of an opportunity
to submit applications to participate in
the HIT supplier accreditation program.
We stated that complete applications
would be considered for the January 1,
2021, designation deadline if received
by February 1, 2020. Regulations for the
approval and oversight of AOs for HIT
organizations are located at 42 CFR part
488, subpart L. The requirements for
HIT suppliers are located at 42 CFR part
486, subpart I.
II. Approval of Deeming Organization
Section 1834(u)(5) of the Act and
regulations at 42 CFR 488.1010 require
that our findings concerning review and
approval of a national accrediting
organization’s requirements consider,
among other factors, the applying
accrediting organization’s requirements
for accreditation; survey procedures;
resources for conducting required
VerDate Sep<11>2014
18:22 Nov 08, 2023
Jkt 262001
surveys; capacity to furnish information
for use in enforcement activities;
monitoring procedures for provider
entities found not in compliance with
the conditions or requirements; and
ability to provide CMS with the
necessary data.
Our rules at 42 CFR 488.1020(a)
require that we publish, after receipt of
an organization’s complete application,
a notice that identifies the national
accrediting body making the request,
describes the nature of the request, and
provides at least a 30-day public
comment period. Pursuant to our rules
at 42 CFR 488.1010(d), we have 210
days from the receipt of a complete
application to publish notice of
approval or denial of the application.
The purpose of this proposed notice
is to inform the public of the Utilization
Review Accreditation Commission
(URAC) request for CMS’ continued
recognition of its HIT accreditation
program. This notice also solicits public
comment on whether URAC’s
requirements meet or exceed the
Medicare requirements of participation
for HIT services.
III. Evaluation of Deeming Authority
Request
In the October 24, 2019, Federal
Register, we published URAC’s initial
application for recognition as an
accreditation organization for HIT (84
FR 57021). On April 1, 2020, we
published notification of their approval
as such an organization, effective March
27, 2020, through March 27, 2024 (84
FR 18243). URAC has since submitted
all the necessary materials to enable us
to make a determination concerning its
request for continued recognition of its
HIT accreditation program. This
application was determined to be
complete on August 30, 2023. Under
section 1834(u)(5) of the Act and 42 CFR
488.1010 (Application and reapplication procedures for national
home infusion therapy accrediting
organizations), our review and
evaluation of URAC will be conducted
in accordance with, but not necessarily
limited to, the following factors:
• The equivalency of URAC’s
standards for HIT as compared with
CMS’ HIT requirements for participation
in the Medicare program.
• URAC’s survey process to
determine the following:
++ The composition of the survey
team, surveyor qualifications, and the
ability of the organization to provide
continuing surveyor training.
++ The comparability of URAC’s to
CMS’ standards and processes,
including survey frequency, and the
ability to investigate and respond
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
appropriately to complaints against
accredited facilities.
++ URAC’s processes and procedures
for monitoring a HIT found out of
compliance with URAC’s program
requirements.
++ URAC’s capacity to report
deficiencies to the surveyed facilities
and respond to the facility’s plan of
correction in a timely manner.
++ URAC’s capacity to provide CMS
with electronic data and reports
necessary for effective assessment and
interpretation of the organization’s
survey process.
++ The adequacy of URAC’s staff and
other resources, and its financial
viability.
++ URAC’s capacity to adequately
fund required surveys.
++ URAC’s policies with respect to
whether surveys are announced or
unannounced, to ensure that surveys are
unannounced.
++ URAC’s agreement to provide CMS
with a copy of the most current
accreditation survey together with any
other information related to the survey
as CMS may require (including
corrective action plans).
++ URAC’s policies and procedures to
avoid conflicts of interest, including the
appearance of conflicts of interest,
involving individuals who conduct
surveys, audits or participate in
accreditation decisions.
++ URAC’s agreement or policies for
voluntary and involuntary termination
of HIT suppliers.
++ URAC’s agreement or policies for
voluntary and involuntary termination
of the HIT AO program.
IV. Collection of Information
Requirements
This document does not impose
information collection requirements,
that is, reporting, recordkeeping, or
third-party disclosure requirements.
Consequently, there is no need for
review by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. 3501 et seq.).
V. Response to Comments
Because of the large number of public
comments, we normally receive on
Federal Register documents, we are not
able to acknowledge or respond to them
individually. We will consider all
comments we receive by the date and
time specified in the DATES section of
this preamble and when we proceed
with a subsequent document, we will
respond to the comments in the
preamble to that document.
The Administrator of the Centers for
Medicare & Medicaid Services (CMS),
E:\FR\FM\09NON1.SGM
09NON1
Federal Register / Vol. 88, No. 216 / Thursday, November 9, 2023 / Notices
Chiquita Brooks-LaSure, having
reviewed and approved this document,
authorizes Chyana Woodyard, who is
the Federal Register Liaison, to
electronically sign this document for
purposes of publication in the Federal
Register.
Chyana Woodyard,
Federal Register Liaison, Centers for Medicare
& Medicaid Services.
[FR Doc. 2023–24850 Filed 11–8–23; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–D–1716]
Compliance Policy for Cosmetic
Product Facility Registration and
Cosmetic Product Listing; Guidance
for Industry; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or we) is
announcing the availability of a final
guidance for industry and the public on
the requirements related to cosmetic
product facility registration and
cosmetic product listing under the
Federal Food, Drug, and Cosmetic Act
(FD&C Act) entitled ‘‘Compliance Policy
for Cosmetic Product Facility
Registration and Cosmetic Product
Listing.’’ This guidance announces
FDA’s intention to delay enforcement of
the requirements related to cosmetic
product facility registration and
cosmetic product listing for an
additional 6 months after the initial
December 29, 2023, deadline.
DATES: The announcement of the
guidance is published in the Federal
Register on November 9, 2023.
ADDRESSES: You may submit either
electronic or written comments on
Agency guidances at any time as
follows:
SUMMARY:
ddrumheller on DSK120RN23PROD with NOTICES1
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
VerDate Sep<11>2014
18:22 Nov 08, 2023
Jkt 262001
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2023–D–1716 for ‘‘Compliance Policy
for Cosmetic Product Facility
Registration and Cosmetic Product
Listing; Guidance for Industry;
Availability.’’ Received comments will
be placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
77323
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of the guidance to the Office of
Cosmetics and Colors, Center for Food
Safety and Applied Nutrition, Food and
Drug Administration, 5001 Campus Dr.,
College Park, MD 20740. Send two selfaddressed adhesive labels to assist that
office in processing your requests. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the guidance.
FOR FURTHER INFORMATION CONTACT:
Jennifer Ross, Office of the Chief
Scientist, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 1, Rm. 4332, Silver Spring,
MD 20993–0002, 301–796–4880 (this is
not a toll-free number), email:
QuestionsAboutMoCRA@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
We are announcing the availability of
a guidance for industry and the public
entitled ‘‘Compliance Policy for
Cosmetic Product Facility Registration
and Cosmetic Product Listing.’’ This
guidance is intended to assist owners or
operators of cosmetic product facilities
that are subject to the requirements
related to facility registration and
responsible persons that are subject to
the requirements related to cosmetic
product listing under the FD&C Act. We
are issuing this guidance consistent
with our good guidance practices (GGP)
regulation (§ 10.115 (21 CFR 10.115)).
We are implementing this guidance
without prior public comment because
we have determined that prior public
E:\FR\FM\09NON1.SGM
09NON1
Agencies
[Federal Register Volume 88, Number 216 (Thursday, November 9, 2023)]
[Notices]
[Pages 77321-77323]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-24850]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS 3452-PN]
Medicare Program; Application by the Utilization Review
Accreditation Commission (URAC) for Continued CMS Approval of Its Home
Infusion Therapy (HIT) Accreditation Program
AGENCY: Centers for Medicare & Medicaid Services (CMS), Health and
Human Services (HHS).
ACTION: Notice with request for comment.
-----------------------------------------------------------------------
SUMMARY: This notice acknowledges the receipt of an application from
the Utilization Review Accreditation Commission (URAC) for continued
approval by the Centers for Medicare & Medicaid Services (CMS) of
URAC's national accrediting organization program for suppliers
providing home infusion therapy (HIT) services and that wish to
participate in the Medicare or Medicaid programs. The statute requires
that within 60 days of receipt of an organization's complete
application, CMS will publish a notice that identifies the national
accrediting body making the request, describes the nature of the
request, and provides at least a 30-day public comment period.
DATES: To be assured consideration, comments must be received at one of
the addresses provided below, by December 11, 2023.
ADDRESSES: In commenting, refer to file code CMS-3452-PN.
Comments, including mass comment submissions, must be submitted in
one of the following three ways (please choose only one of the ways
listed):
1. Electronically. You may submit electronic comments on this
regulation to https://www.regulations.gov. Follow the ``Submit a
comment'' instructions.
2. By regular mail. You may mail written comments to the following
address ONLY: Centers for Medicare & Medicaid Services, Department of
Health and Human Services, Attention: CMS-3452-PN, P.O. Box 8016,
Baltimore, MD 21244-8010.
Please allow sufficient time for mailed comments to be received
before the close of the comment period.
3. By express or overnight mail. You may send written comments to
the following address ONLY: Centers for Medicare & Medicaid Services,
Department of Health and Human Services, Attention: CMS-3452-PN, Mail
Stop C4-26-05, 7500 Security Boulevard, Baltimore, MD 21244-1850.
For information on viewing public comments, see the beginning of
the SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT: Shannon Freeland, (410) 786-4348.
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All comments received before the
close of the comment period are available for viewing by the public,
including any personally identifiable or confidential business
information that is included in a comment. We post all comments
received before the close of the comment period on the following
website as soon as possible after they have been received: https://www.regulations.gov. Follow the search instructions on that website to
view public comments. We will not post on Regulations.gov public
comments that make threats to individuals or institutions or suggest
that the individual will take actions to harm the individual. We
continue to encourage individuals not to submit duplicative comments.
We will post acceptable comments from multiple unique commenters even
if the content is identical or nearly identical to other comments.
I. Background
Home infusion therapy (HIT) is a treatment option for Medicare
beneficiaries with a wide range of acute and chronic conditions.
Section 5012 of the 21st Century Cures Act (Pub. L. 114-255, enacted
December 13, 2016) added section 1861(iii) to the Social Security Act
(the Act), establishing a new Medicare benefit for HIT services.
Section 1861(iii)(1) of the Act defines ``home infusion therapy'' as
professional services, including nursing services; training and
education not otherwise covered under the Durable Medical Equipment
(DME) benefit; remote monitoring; and other monitoring services. HIT
must be furnished by a qualified HIT supplier and furnished in the
individual's home. The individual must:
Be under the care of an applicable provider (that is,
physician, nurse practitioner, or physician assistant); and
Have a plan of care established and periodically reviewed
by a physician in
[[Page 77322]]
coordination with the furnishing of home infusion drugs under Part B,
that prescribes the type, amount, and duration of infusion therapy
services that are to be furnished.
Section 1861(iii)(3)(D)(i)(III) of the Act requires that a
qualified HIT supplier be accredited by an accrediting organization
(AO) designated by the Secretary in accordance with section 1834(u)(5)
of the Act. Section 1834(u)(5)(A) of the Act identifies factors for
designating AOs and in reviewing and modifying the list of designated
AOs. These statutory factors are as follows:
The ability of the organization to conduct timely reviews
of accreditation applications.
The ability of the organization to take into account the
capacities of suppliers located in a rural area (as defined in section
1886(d)(2)(D) of the Act).
Whether the organization has established reasonable fees
to be charged to suppliers applying for accreditation.
Such other factors as the Secretary determines
appropriate.
Section 1834(u)(5)(B) of the Act requires the Secretary to
designate AOs to accredit HIT suppliers furnishing HIT not later than
January 1, 2021. Section 1861(iii)(3)(D)(i)(III) of the Act requires a
``qualified home infusion therapy supplier'' to be accredited by a CMS-
approved AO, pursuant to section 1834(u)(5) of the Act.
On March 1, 2019, we published a solicitation notice entitled,
``Medicare Program; Solicitation of Independent Accrediting
Organizations to Participate in the Home Infusion Therapy Supplier
Accreditation Program'' (84 FR 7057). This notice informed national AOs
that accredit HIT suppliers of an opportunity to submit applications to
participate in the HIT supplier accreditation program. We stated that
complete applications would be considered for the January 1, 2021,
designation deadline if received by February 1, 2020. Regulations for
the approval and oversight of AOs for HIT organizations are located at
42 CFR part 488, subpart L. The requirements for HIT suppliers are
located at 42 CFR part 486, subpart I.
II. Approval of Deeming Organization
Section 1834(u)(5) of the Act and regulations at 42 CFR 488.1010
require that our findings concerning review and approval of a national
accrediting organization's requirements consider, among other factors,
the applying accrediting organization's requirements for accreditation;
survey procedures; resources for conducting required surveys; capacity
to furnish information for use in enforcement activities; monitoring
procedures for provider entities found not in compliance with the
conditions or requirements; and ability to provide CMS with the
necessary data.
Our rules at 42 CFR 488.1020(a) require that we publish, after
receipt of an organization's complete application, a notice that
identifies the national accrediting body making the request, describes
the nature of the request, and provides at least a 30-day public
comment period. Pursuant to our rules at 42 CFR 488.1010(d), we have
210 days from the receipt of a complete application to publish notice
of approval or denial of the application.
The purpose of this proposed notice is to inform the public of the
Utilization Review Accreditation Commission (URAC) request for CMS'
continued recognition of its HIT accreditation program. This notice
also solicits public comment on whether URAC's requirements meet or
exceed the Medicare requirements of participation for HIT services.
III. Evaluation of Deeming Authority Request
In the October 24, 2019, Federal Register, we published URAC's
initial application for recognition as an accreditation organization
for HIT (84 FR 57021). On April 1, 2020, we published notification of
their approval as such an organization, effective March 27, 2020,
through March 27, 2024 (84 FR 18243). URAC has since submitted all the
necessary materials to enable us to make a determination concerning its
request for continued recognition of its HIT accreditation program.
This application was determined to be complete on August 30, 2023.
Under section 1834(u)(5) of the Act and 42 CFR 488.1010 (Application
and re-application procedures for national home infusion therapy
accrediting organizations), our review and evaluation of URAC will be
conducted in accordance with, but not necessarily limited to, the
following factors:
The equivalency of URAC's standards for HIT as compared
with CMS' HIT requirements for participation in the Medicare program.
URAC's survey process to determine the following:
++ The composition of the survey team, surveyor qualifications, and
the ability of the organization to provide continuing surveyor
training.
++ The comparability of URAC's to CMS' standards and processes,
including survey frequency, and the ability to investigate and respond
appropriately to complaints against accredited facilities.
++ URAC's processes and procedures for monitoring a HIT found out
of compliance with URAC's program requirements.
++ URAC's capacity to report deficiencies to the surveyed
facilities and respond to the facility's plan of correction in a timely
manner.
++ URAC's capacity to provide CMS with electronic data and reports
necessary for effective assessment and interpretation of the
organization's survey process.
++ The adequacy of URAC's staff and other resources, and its
financial viability.
++ URAC's capacity to adequately fund required surveys.
++ URAC's policies with respect to whether surveys are announced or
unannounced, to ensure that surveys are unannounced.
++ URAC's agreement to provide CMS with a copy of the most current
accreditation survey together with any other information related to the
survey as CMS may require (including corrective action plans).
++ URAC's policies and procedures to avoid conflicts of interest,
including the appearance of conflicts of interest, involving
individuals who conduct surveys, audits or participate in accreditation
decisions.
++ URAC's agreement or policies for voluntary and involuntary
termination of HIT suppliers.
++ URAC's agreement or policies for voluntary and involuntary
termination of the HIT AO program.
IV. Collection of Information Requirements
This document does not impose information collection requirements,
that is, reporting, recordkeeping, or third-party disclosure
requirements. Consequently, there is no need for review by the Office
of Management and Budget under the authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501 et seq.).
V. Response to Comments
Because of the large number of public comments, we normally receive
on Federal Register documents, we are not able to acknowledge or
respond to them individually. We will consider all comments we receive
by the date and time specified in the DATES section of this preamble
and when we proceed with a subsequent document, we will respond to the
comments in the preamble to that document.
The Administrator of the Centers for Medicare & Medicaid Services
(CMS),
[[Page 77323]]
Chiquita Brooks-LaSure, having reviewed and approved this document,
authorizes Chyana Woodyard, who is the Federal Register Liaison, to
electronically sign this document for purposes of publication in the
Federal Register.
Chyana Woodyard,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2023-24850 Filed 11-8-23; 8:45 am]
BILLING CODE 4120-01-P